Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib + cetuximab versus chemotherapy in second-line KRAS G12C-mutated advanced colorectal cancer
NL-OMON59743Phase 3Completed
- Sponsor
- Mirati Therapeutics
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of adagrasib and cetuximab in colorectal cancer (CRC) (2 arms), sponsored by Mirati Therapeutics. Primary endpoints: Overall survival and Progression-free survival. Started Jun 2022; status: completed.
02
Drugs
adagrasibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON59743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59743.